Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


GPC Biotech acquires assets of Axxima Pharmaceuticals
Axxima Pharmaceuticals is a 2003 Tornado100 Winner


Martinsried/Munich (Germany) and U.S. Research and Development Facilities in Waltham/Boston, Mass. and Princeton, N.J., March 2, 2005 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced the acquisition of material assets of Axxima Pharmaceuticals AG. Axxima, a kinase drug discovery firm based in Munich, filed for insolvency in December 2004. Axxima’s assets were transferred to a newly formed holding company in which certain Axxima investors led by TVM Techno Venture Management and other new investors injected an additional net € 8.7 million in cash. GPC Biotech will purchase the holding company in a cash neutral transaction for €13.7 million by issuing approximately 1.3 million new shares at a price of €10.47.

“This strategic acquisition is enabling us to add important expertise in the area of kinase-based drug discovery at a very favorable price,” said Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer of GPC Biotech. “This expertise is highly complementary to our own internal capabilities. Axxima’s signal transduction biology comes out of the laboratory of Dr. Axel Ullrich at the Max-Planck-Institute for Biochemistry, one of the world’s most renowned laboratories in this field, and Axxima’s medicinal chemistry team is also very experienced in kinase inhibitor chemistry. Both will provide a wonderful addition to our top-notch drug discovery groups in Munich and Waltham, MA, USA. We believe this acquisition will assist us in achieving our longer-term goal of further growing our drug pipeline with novel mechanism-based therapies to treat cancer. The cash infusion associated with this transaction allows us to significantly strengthen our mechanism-based drug discovery efforts without tapping into the financial resources earmarked for our advanced clinical oncology programs, particularly satraplatin which is currently in a Phase 3 registrational trial.”

Axxima Pharmaceuticals AG was a drug discovery company in the field of kinase inhibition. Axxima started operations in Martinsried in 1998 and was founded by a group of experienced
scientists, led by Dr. Axel Ullrich, a former leading scientist at Genentech and co-founder of Sugen Inc. Axxima had raised a total of more than €50 million since its inception and was focussing initially on infectious diseases and over the last years on cancer.

GPC Biotech will purchase the holding company to which material assets of Axxima and the net €8.7 million cash infusion from investors were transferred and will not be responsible for Axxima’s liabilities, unless expressly assumed in the asset purchase agreement. GPC Biotech is also receiving all of Axxima’s patents, patent applications and know-how as well as several early-stage drug discovery programs in the areas of cancer. Additional pre-clinical and early clinical programs in infectious disease will also be transferred to GPC Biotech and might be partnered going forward. The Company also expects to hire approximately forty employees from Axxima to further strengthen its own drug discovery capabilities. GPC Biotech will make milestone payments to the insolvency receiver of Axxima for the entry of three compounds protected by Axxima’s patent estate into clinical trials, up to a maximum total amount of €9 million.

The shares will be issued to the investors in the holding company from authorized capital. The average closing price of GPC Biotech shares for the last 30 trading days on Xetra was used to calculate the share price for the transaction. This average share price was €10.47, representing a premium to the closing price of March 1, 2005 on Xetra of 8.6%. This transaction will result in a dilution of approximately 4.6%. The newly issued shares are subject to a minimum six-month lock-up period.


GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate - satraplatin - is currently in<


Publisher Contact Information:

Axxima Pharmaceuticals AG
+49 (0)89 8565-2600
martin.braendle@gpc-biotech.com

Company profile of Axxima Pharmaceuticals AG (Acquired by GPC Biotech)
Past press releases of Axxima Pharmaceuticals AG (Acquired by GPC Biotech).

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.